<DOC>
	<DOC>NCT02815267</DOC>
	<brief_summary>This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.</brief_summary>
	<brief_title>A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Has facial acne vulgaris with: 20 to 50 inflammatory lesions (papules, pustules, and nodules); 25 to 100 noninflammatory lesions (open and closed comedones); no more than 2 nodules on the face; and IGA score of moderate (3) to severe (4) Willing to use only the supplied nonmedicated cleanser (Cetaphil Gentle Skin Cleanser) and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne) or any dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations Sunburn on the face Severe systemic disease, which might interfere with the conduct of the study or the interpretation of the results. Abnormal baseline laboratory values that are considered clinically significant Allergy to tetracyclineclass antibiotics or to any ingredient in the study drug Pseudomembranous colitis or antibioticassociated colitis</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acne</keyword>
</DOC>